Glenmark Pharmaceuticals has announced that GRC 27864 is entering human trials. GRC 27864 targets Microsomal Prostaglandin E synthase-1 (mPGES-1) as a therapeutic target in pain management. Selective mPGES-1 inhibitors are expected to inhibit increased prostaglandin E2 (PGE2) production in the disease state without affecting other prostanoid metabolites and, consequently, may be devoid of the GI (gastrointestinal) and cardiovascular side effects seen with NSAIDs and COX-2 inhibitors, respectively.
Recent reports indicate that more than 1.5 billion people worldwide suffer from chronic pain in some form with a direct correlation between incidence rates and increasing age. It is estimated that, at some point in their lives, 20% of the global adult population suffers from pain with 10% of newly diagnosed cases of chronic pain being added each year.
Despite incremental advances in opioid-based or cyclooxygenase-based therapies, there has been little success in identifying and developing treatments based upon new targets that might overcome the limitations of currently available analgesic treatments for the management of chronic pain.
Glenmark has completed preclinical studies and Phase 1 enabling GLP studies for its selected lead molecule, GRC 27864 and has filed a Phase 1 application for first-in-human trial with the MHRA, UK. The Phase 1 studies are to be initiated soon and are likely to get completed by January 2015. Following this, Glenmark will also be initiating a proof of concept study in patients with acute pain.
PGE2 is a lipid mediator produced by arachidonic acid, which serves pivotal functions in disease conditions associated with fever, inflammation, and pain. mPGES-1 is a terminal enzyme in the PGE2 biosynthetic pathway and solely responsible for PGE2 synthesis during inflammation. Over expression of mPGES-1 is observed in various nonclinical animal models, such as RA, OA, atherosclerosis, experimental autoimmune encephalomyelitis, cancer, inflammatory bowel disease, multiple sclerosis, periodontitis, fibrosis, Parkinson's disease, and Alzheimer's disease.
On the contrary, mPGES-1 deleted cells produced significantly lower levels of PGE2 in response to inflammatory stimuli and were less sensitive to inflammatory and neuropathic pain, and refractory to the development of joint pathology in rodent arthritis models. Selective mPGES-1 inhibitors are expected to inhibit increased PGE2 production in the disease state without affecting other prostanoid metabolites and are, consequently, may be devoid of the GI and cardiovascular side effects seen with NSAIDs and COX-2 inhibitors, respectively, potentially making them suitable for chronic treatment of inflammatory diseases that are accompanied with pain.
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Phase-Change Materials Set New Speed Limit For Silicon
- M60-UCD1: Tiny Galaxy, Supermassive Black Hole
- More Children Making Music, But Are Lessons Too Conventional?
- Life After The 125 GeV Higgs: What Is Left Of Two-Higgs Doublet Models
- Watching Neurons Learn: Learning New Ideas Is More Difficult
- Witness The Singularity AI Nanotech Co-Evolutionary Merger
- John Ellis On The Ascent Of The Standard Model
- "I only have one problem with this article, and it is your implication that atheism is the lack..."
- "Sorry, I do not quite get your point. What do you object to ? The fact that the SM lagrangian remains..."
- "Recently someone requested my opinion on a book to read authored by a woman who runs a health spa..."
- "Bad idea. A person may be having those feelings for any number of reasons. A man may be angry because..."
- " Quantum Mechanics (intellectual dishonesty) at its finest, a never ending logical fallacy of moving..."
- Gibbon genome sequence deepens understanding of primates rapid chromosomal rearrangements
- Combining antibodies, iron nanoparticles and magnets steers stem cells to injured organs
- Messier 54 lithium: This star cluster is not what it seems
- Sharks more abundant on healthy coral reefs
- Using plants to produce enzyme may provide treatment for high blood pressure in lungs